No Abstract BioWorld International CorrespondentPARIS - Endotis Pharma, which is developing small-glyco drugs for applications in thrombosis and oncology, has obtained public funding of €4.5 million (US6.1 million) from three sources to finance ongoing research programs.

Despite Monday's carnage on stock exchanges across the globe, OctoPlus NV posted a 13.6 percent rise in its share price on news that it could earn up to $149 million in up front, milestone and production-related payments from out-licensing its controlled-release formulation of alpha interferon, Locteron, to its co-development partner Biolex Therapeutics Inc. It also would receive royalties on product sales. (BioWorld International)